1. Marshall EK, Lynch V, Smith HW. On dichloroethylsulfide (Mustard gas). II. Variation in susceptibility of the skin to dichloroethylsulfide. JPET 1918; 12: 291-301.

2. Weber WW. Populations and genetic polymorphisms. Molec Diagnosis 1999; 4(4):299-307.

Cavalli-Sforza LL, Menozzi C, Piazza A. The History and Geography of Human Genes, 1st ed. Princeton, NJ: Princeton University Press, 1994. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003; 348(12):1170-1175.

Hirschfeld L, Hirschfeld H. Serological differences between the blood of different races. Lancet 1919; 2(Oct 18):675-679.

Itano H, Robinson ER. Genetic control of the a- and ß-chains of hemoglobin. Proc Natl Acad Sci USA 2004; 46(11):1492-1501.

Ingram VM. Gene evolution and the haemoglobins. Nature 1961; 189:704-708. Smithies O, Connell GE, Dixon GH. Chromosomal rearrangements and the evolution of haptoglobin genes. Nature 1962; 196:232-236.

Baglioni C. The fusion of two peptide chains in hemoglobin Lepore and its interpretation as a genetic deletion. Proc Natl Acad Sci USA 1962; 48:1880-1886. Foster MW, Sharp RR. Race, ethnicity, and genomics: Social classifications as proxies of biological heterogeneity. Genome Res 2002; 12(6):844-850. Barbujani G, Magagni A, Minch E, Cavalli-Sforza LL. An apportionment of human DNA diversity. Proc Natl Acad Sci USA 1997; 94(9, Apr 29):4516-4519. Schwartz RS. Racial profiling in medical research. N Engl J Med 2001; 344(18): 1392-1393.

Cavalli-Sforza LL, Piazza A, Menozzi P, Mountain J. Reconstruction of human evolution: Bringing together genetic, archaeological, and linguistic data. Proc Natl Acad Sci USA 1988; 85(16):6002-6006.

Goldstein DB, Ruiz LA, Cavalli-Sforza LL, Feldman MW. Genetic absolute dating based on microsatellites and the origin of modern humans. Proc Natl Acad Sci USA 1995; 92(15):6723-6727.

Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344(18):1351-1357. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344(18):1358-1365. Wood AJ. Racial differences in the response to drugs—pointers to genetic differences. N Engl J Med 2001; 344(18):1394-1396.

Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG, et al. Population genetic structure of variable drug response. Nat Genet 2001; 29(3): 265-269.

Kaplan JB, Bennett T. Use of race and ethnicity in biomedical publication. JAMA 2003; 289(20):2709-2716.

Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med 2003; 348(12):1166-1170.

Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 2001; 23(1):75-77. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20):2049-2057.

Xie H-G, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41:815-850. Wood Jr WB. Anemia during sulfanilamide therapy. JAMA 1938; 111(Nov 19): 1916-1919.

25. Earle DP, Bigelow FS, Zubrod CG, Kane CA. Studies on the chemotherapy of the human malarias. IX. Effect of pamaquine on the blood cells of man. J Clin Invest 1948; 27:121-129.

26. Hockwald RS, Arnold J, Clayman CB. Toxicity of primaquine in negroes. JAMA 1952; 149:1568-1570.

27. Dern RJ, Weinstein IM, Leroy GV, Talmage DW, Alving AS. The hemolytic effect of primaquine. I. The localization of the drug-induced hemolytic defect in primaquine-sensitive individuals. J Lab Clin Med 1954; 43(2):303-309.

28. Flanagan CL, BeutlerE, Dern RJ, Alving AS. Biochemical changes in erythrocytes during hemolysis induced by aniline derivatives. J Lab Clin Med 1954; 46:814.

29. Beutler E, Dern RJ, Flanagan CL, Alving AS. The hemolytic effect of primaquine. VII. Biochemical studies of drug-sensitive erythrocytes. J Lab Clin Med 1955; 45(2):286-295.

30. Beutler E. The glutathione instability of drug-sensitive red cells; a new method for the in vitro detection of drug sensitivity. J Lab Clin Med 1957; 49(1):84-95.

31. Kirkman HN. Glucose-6-phosphate dehydrogenase variants and drug-induced hemolysis. Ann NY Acad Sci 1968; 151(2):753-764.

32. Hirono A, Beutler E. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Proc Natl Acad Sci USA 1988; 85(11):3951-3954.

33. Beutler E. The molecular biology of G6PD variants and other red cell enzyme defects. Annu Rev Med 1992; 43:47-59.

34. Weber WW. The acetylator genes and drug response. New York: Oxford University Press, 1987.

35. Sunahara S, Urano M, Ogawa M. Genetical and geographic studies on isoniazid inactivation. Science 1961; 134:1530-1531.

36. Karim AK, Elfellah MS, Evans DA. Human acetylator polymorphism: Estimate of allele frequency in Libya and details of global distribution. J Med Genet 1981; 18(5):325-330.

37. Lewontin RC. The Genetic Basis of Evolutionary Change. New York: Columbia University Press, 1974.

38. Cavalli-Sforza LL, Bodmer WF. The Genetics of Human Populations. San Francisco: W.H. Freeman, 1971.

39. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, et al. Human acetyltransferase polymorphisms. Mutat Res 1997; 376(1-2):61-70.

40. Levy GG, Weber WW. Interindividual variability of arylamine acetyltransferases. In: Pacifici G, Pelkonen O, editors. Interindividual variability in drug metabolism in man. London: Taylor & Francis, 2001: 333-357.

41. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydrox-ylation of debrisoquine: A case report with implication for treatment with nortri-ptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7(4):478-480.

42. Arias TD, Jorge LF, Inaba T. No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: The Cunas of Panama. Br J Clin Pharmacol 1986; 21(5):547-548.

43. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369(1):23-37.

44. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274(1):516-520.

45. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6(3):193-201.

46. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7(3):193-202.

47. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12:102-107.

48. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacoge-netics 1997; 7(3):187-191.

49. Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37(5):512-521.

50. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90(24):11825-11829.

51. Ingelman-Sundberg M. The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics. Arch Toxicol Suppl 1997; 19:3-13.

52. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278(1):441-446.

53. Agundez JA, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57(3):265-269.

54. Bernal ML, Sinues B, Johansson I, McLellan RA, Wennerholm A, Dahl ML, et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 1999; 9(5):657-660.

55. Ingelman-Sundberg M. The human genome project and novel aspects of cyto-chrome P450 research. Toxicol Appl Pharmacol 2005; 207(2 Suppl):52-56.

56. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8(2):129-135.

57. Evans DA, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995; 5(2):64-71.

58. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: Implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003; 78(12):1479-1487.

59. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86(3):367-377.

60. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382(6593):722-725.

61. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273(5283):1856-1862.

62. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392(6673):293-296.

63. Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-delta 32 HIV-resistance allele. Proc Natl Acad Sci USA 2003; 100(25):15276-15279.

64. Shibuya A, Yasunami M, Yoshida A. Genotype of alcohol dehydrogenase and aldehyde dehydrogenase loci in Japanese alcohol flushers and nonflushers. Hum Genet 1989; 82(1):14-16.

65. Higuchi S, Muramatsu T, Shigemori K, Saito M, Kono H, Dufour MC, et al. The relationship between low Km aldehyde dehydrogenase phenotype and drinking behavior in Japanese. J Stud Alcohol 1992; 53(2):170-175.

66. Dalen P, Frengell C, Dahl ML, Sjoqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19(5):543-544.

67. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351(27):2827-2831.

68. Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002; 71(1):77-88.

69. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7(5): 375-379.

70. Özdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62(3):334-347.

71. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53(11):1605-1612.

72. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48(5):943-950.

73. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448(1):105-110.

74. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331(6155):442-446.

75. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4(6):285-299.

76. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369(6475):64-67.

77. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochro-matosis. Nat Genet 1996; 13(4):399-408.

78. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46(3):452-459.

79. McCarver DG, Byun R, Hines RN, Hichme M, Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 1998; 152(1):276-281.

80. Buhler R, Hempel J, Von Wartburg JP, Jornvall H. Human liver alcohol dehydrogenase: The unique properties of the ''atypical'' isoenzyme beta 2 beta 2-Bern can be explained by a single base mutation. Alcohol 1985; 2(1):47-51.

81. McCarver DG, Thomasson HR, Martier SS, Sokol RJ, Li T. Alcohol dehydro-genase-2*3 allele protects against alcohol-related birth defects among African Americans. J Pharmacol Exp Ther 1997; 283(3):1095-1101.

82. McLellan RA, Oscarson M, Alexandrie AK, Seidegard J, Evans DA, Rannug A, et al. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. Mol Pharmacol 1997; 52(6):958-965.

83. Kruse TA, Bolund L, Grzeschik KH, Ropers HH, Sjostrom H, Noren O, et al. The human lactase-phlorizin hydrolase gene is located on chromosome 2. FEBS Lett 1988; 240(1-2):123-126.

84. Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I. Identification of a variant associated with adult-type hypolactasia. Nat Genet 2002; 30(2): 233-237.

85. Wang Y, Harvey CB, Pratt WS, Sams VR, Sarner M, Rossi M, et al. The lactase persistence/non-persistence polymorphism is controlled by a cis-acting element. Hum Mol Genet 1995; 4(4):657-662.

86. Harvey CB, Pratt WS, Islam I, Whitehouse DB, Swallow DM. DNA polymorphisms in the lactase gene. Linkage disequilibrium across the 70-kb region. Eur J Hum Genet 1995; 3(1):27-41.

87. Mulcare CA, Weale ME, Jones AL, Connell B, Zeitlyn D, Tarekegn A, et al. The T allele of a single-nucleotide polymorphism 13.9 kb upstream of the lactase gene (LCT) (C-13.9kbT) does not predict or cause the lactase-persistence phenotype in Africans. Am J Hum Genet 2004; 74(6):1102-1110.

88. Tishkoff SA, Reed FA, Ranciaro A, Voight BF, Babbitt CC, Silverman JS, et al. Convergent adaptation of human lactase persistence in Africa and Europe. Nat Genet 2007; 39(1):31-40.

89. Wooding SP. Following the herd. Nat Genet 2007; 39(1):7-8.

90. Knight JC. Allele-specific gene expression uncovered. Trends Genet 2004; 20(3):113-116.

91. Knight JC. Regulatory polymorphisms underlying complex disease traits. J Mol Med 2005; 83(2):97-109.

92. Wilson W III, Pardo-Manuel d V, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84(4):707-714.

93. King MC, Wilson AC. Evolution at two levels in humans and chimpanzees. Science 1975; 188(4184):107-116.

94. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314(5807):1930-1933.

95. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A ''silent'' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315(5811):525-528.

96. Komar AA. Genetics. SNPs, silent but not invisible. Science 2007; 315(5811): 466-467.

97. Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG. Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet 2007; 39:226-231.

98. The International HapMap Consortium. The International HapMap Project. Nature 2003; 426(18/25 Dec):789-796.

99. Foster MW, Sharp RR. Genetic research and culturally specific risks: One size does not fit all. Trends Genet 2000; 16(2):93-95.

100. Andrews L, Nelkin D. Whose body is it anyway? Disputes over body tissue in a biotechnology age. Lancet 1998; 351(9095):53-57.

Was this article helpful?

0 0

Post a comment